Evaluating the incidence and prevalence of perioral dermatitis in the United States: A population-level study.
Need to claim your poster? Find the KiKo table at the conference and they'll help
you get set up.
Presented at: Society for Investigative Dermatology 2025
Date: 2025-05-07 00:00:00
Views: 2
Summary: Abstract Body: Perioral dermatitis has a paucity of epidemiologic data, with prior studies limited by small sample sizes from single institutions. Using the TriNetX US Collaborative Network (69 healthcare organizations), we conducted a multi-institutional, population-based study to estimate the incidence and prevalence of perioral dermatitis from 1/1/2017 to 12/13/2023 in the United States, identifying perioral dermatitis in patients with >1 ICD-10-CM code for L71.0. Overall and annualized incidence and prevalence estimates were determined, and 95% confidence intervals were calculated via normal approximation. We identified 135,163 patients with incident perioral dermatitis (incidence proportion (IP) [95% CI] = 0.158% [0.157, 0.159]) and 286,971 patients with prevalent perioral dermatitis (prevalence proportion (PP) [95% CI] = 0.336% [0.334, 0.337]). Patients 0-9 years old had the highest incidence of perioral dermatitis (IP [95% CI] = 0.145% [0.143, 0.147]), followed by patients 30-39 years old (IP [95% CI] = 1.43% [0.141, 0.145]). Patients 50-59 years old had the highest prevalence of perioral dermatitis (PP [95% CI] = 0.308% [0.306, 0.311]). Perioral dermatitis incidence in females (IP [95% CI] = 0.196% [0.195, 0.198]) was higher than in males (IP [95% CI] = 0.080% [0.079, 0.081]), and prevalence in females (PP [95% CI] = 0.420% [0.418, 0.422]) was higher than in males (PP [95% CI] = 0.186% [0.185, 0.187]). Both the annual incidence and prevalence of perioral dermatitis increased overall from 2017 to 2023. Overall, our study provides important population-level data on perioral dermatitis. Christopher J. Thang<sup>1, 2</sup>, David Garate<sup>1</sup>, Jenny Lai<sup>3, 4</sup>, George Golovko<sup>5</sup>, Michael G. Wilkerson<sup>6</sup>, John S. Barbieri<sup>4</sup> 1. The University of Texas Medical Branch John Sealy School of Medicine, Galveston, TX, United States. 2. Department of Dermatology, Massachusetts General Hospital Neuroscience Institute, Boston, MA, United States. 3. Harvard Medical School, Boston, MA, United States. 4. Department of Dermatology, Brigham and Women's Hospital, Boston, MA, United States. 5. Department of Pharmacology and Toxicology, The University of Texas Medical Branch at Galveston, Galveston, TX, United States. 6. Department of Dermatology, The University of Texas Medical Branch at Galveston, Galveston, TX, United States. Clinical Research: Epidemiology and Observational Research